Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Arcus Biosciences announced that its Compensation Committee granted three new employees options to purchase a total of 16,300 shares of the company's common stock at an exercise price of $16.28 per share. The closing price on May 23, 2024, determined this amount.
Additionally, the company awarded restricted stock units to acquire a total of 8,150 shares. These equity awards align with the company's 2020 Inducement Plan, approved by the Board of Directors in January 2020 under the “inducement exception” provided by NYSE Rule 303A.08.
Arcus Biosciences, Inc. announced the grant of employment inducement options and restricted stock units to new employees. The total grant includes 141,100 shares of common stock options and 70,555 restricted stock units. The awards were issued under the Company's 2020 Inducement Plan, approved by the Board of Directors in January 2020.
Arcus Biosciences, Inc. (NYSE:RCUS) reported financial results for Q1 2024 and provided a pipeline update focusing on TIGIT, adenosine axis, HIF-2a, AXL, and PD-1 molecules targeting lung, gastrointestinal, and kidney cancers. Key updates include data presentations at ASCO, Phase 3 studies enrollment, and expansion cohorts for casdatifan in ccRCC. With $1.1 billion in cash, Arcus is well-positioned for pipeline advancement. Financially, Q1 2024 saw increased revenues, R&D expenses, and cash reserves to fund operations into 2027.
Arcus Biosciences (NYSE:RCUS) will participate in a fireside chat at the Bank of America Healthcare Conference 2024. The company focuses on developing cancer treatments and will have a live webcast on May 16th, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.